Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19496642 | 0.91 | TSHR (0.35) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL5933523 | 0.82 | — | — | |
| SCHEMBL26665314 | 0.82 | ANPEP (0.52) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL8337070 | 0.82 | — | — | |
| SCHEMBL24512169 | 0.82 | — | — | |
| SCHEMBL23157056 | 0.82 | — | — | |
| SCHEMBL56311 | 0.82 | ANPEP (0.65) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL101928 | 0.79 | — | — | |
| SCHEMBL5027780 | 0.79 | — | — | |
| SCHEMBL15251619 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11091475-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | ANPEP 4115/4885ERAP1 1823/4885ERAP2 2360/4885 |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ANPEP 4115/4885ERAP1 1823/4885ERAP2 2360/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ANPEP 4115/4885ERAP1 1823/4885ERAP2 2360/4885 |
| US-11091475-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | ANPEP 4115/4885ERAP1 1823/4885ERAP2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.